Impact of Using the Race-Free 2021 CKD-EPI Creatinine Equation on Treatment Effects on GFR-Based End Points in Clinical Trials

Am J Kidney Dis. 2024 Feb;83(2):269-272. doi: 10.1053/j.ajkd.2023.05.012. Epub 2023 Aug 30.

Authors

Juhi Chaudhari¹, Shiyuan Miao¹, Julia B Lewis², Hiddo J L Heerspink³, Andrew S Levey¹, Lesley A Inker⁴

Affiliations

¹ Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.
² Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
⁴ Division of Nephrology, Tufts Medical Center, Boston, Massachusetts. Electronic address: [email protected].

PMID: 37657637
DOI: 10.1053/j.ajkd.2023.05.012

No abstract available

Publication types

Letter

MeSH terms

Clinical Trials as Topic
Creatinine*
Glomerular Filtration Rate
Humans
Renal Insufficiency, Chronic* / therapy

Substances

Creatinine